BCM
AVEO

Bienville Capital Management’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Bienville Capital Management’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-2,000
Closed -$17K – 99
2014
Q4 		$17K Buy
+2,000
New +$18.3K 0.01% 103

Other funds holding AVEO

SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
DVC
Deer VI & Co Larchmont, New York $2.23M AUM 9.32% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
GX
Greylock XI Cambridge, Massachusetts $7.71M AUM 28.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bienville Capital Management's AVEO Position: Q1 2015 in Review

Bienville Capital Management sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2015, closing a stake of 2,000 shares — an estimated $17K sold.

Bienville Capital Management first reported a position in AVEO in Q4 2014 and held it in 1 quarter. The position peaked at $17K in Q4 2014. 49 funds tracked by Wall St. Rank hold AVEO as of Q1 2015.

  • Bienville Capital Management reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2015 after selling out during the quarter.
  • Bienville Capital Management sold 2,000 AVEO Pharmaceuticals, Inc. shares in Q1 2015, an estimated $17K.
  • Bienville Capital Management first reported a position in AVEO Pharmaceuticals, Inc. in Q4 2014 and held it in 1 quarter.
  • Bienville Capital Management's AVEO Pharmaceuticals, Inc. position peaked at $17K in Q4 2014.
  • 49 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2015.

Based on Bienville Capital Management's 13F filing for Q1 2015, filed 13 May 2015.